99 Wall Street, Suite 232, New York, NY 10005

需要帮忙?呼叫(800) 991-3756

Class Action Cases

A class action has been filed on behalf of Apyx Medical Corporation Investors. Click "Join this Class Action" above.

Attorneys

(English) Apyx Medical Corporation

Join Class Action »

对不起,此内容只适用于美式英文

Press Release

(English) SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Apyx Medical Corporation – APYX

New York, N.Y., April 26, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Apyx Medical Corporation (NASDAQ: APYX) from August 1, 2018 through April 1, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages Apyx investors under the federal securities laws.

To join the Apyx class action, go to http://zhanginvestorlaw.com/cases/apyx-medical-corporation/ or call Sophie Zhang, Esq. or toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the clinical study on the use of J-Plasma, a plasma-based surgical product for cutting, coagulation, and ablation of soft tissue, for dermal resurfacing had not met its primary efficacy endpoint; (2) the clinical study did not support Apyx’s application for regulatory clearance; (3) Apyx was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and (4) as a result of the foregoing, Defendants’ positive statements about Apyx’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 17, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/apyx-medical-corporation/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Pawar Law Group toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.
——————————-